Liquidia Technologies, Inc. (LQDA): Price and Financial Metrics
LQDA Price/Volume Stats
| Current price | $12.55 | 52-week high | $16.99 |
| Prev. close | $12.95 | 52-week low | $5.71 |
| Day low | $12.40 | Volume | 1,125,700 |
| Day high | $13.07 | Avg. volume | 951,780 |
| 50-day MA | $14.59 | Dividend yield | N/A |
| 200-day MA | $9.87 | Market Cap | 954.15M |
LQDA Stock Price Chart Interactive Chart >
Liquidia Technologies, Inc. (LQDA) Company Bio
Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. The company was founded in 2004 and is based in Morrisville, North Carolina.
Latest LQDA News From Around the Web
Below are the latest news stories about LIQUIDIA CORP that investors may wish to consider to help them evaluate LQDA as an investment opportunity.
Biotech CEOs Are Buying Up Their Surging StocksShares of Cibus, OmniAb, and Liquidia—three small biotechs—have seen big gains this year. Their CEOs just bought more stock. |
Peabody Energy, Janus International, and More Stocks See Action From Activist InvestorsActivists file with the SEC on Liquidia, Janus International Group, Peabody Energy, Disc Medicine, and Blue Bird. |
Industry Analysts Just Upgraded Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts By 38%Liquidia Corporation ( NASDAQ:LQDA ) shareholders will have a reason to smile today, with the analysts making... |
Independent Director of Liquidia Picks Up 5.3% More StockThose following along with Liquidia Corporation ( NASDAQ:LQDA ) will no doubt be intrigued by the recent purchase of... |
U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)Liquidia will pursue final FDA approval for YUTREPIA™ (treprostinil) inhalationLiquidia will immediately request that District Court set aside injunction tied to ‘793 patent MORRISVILLE, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) announced that the U.S. Court of Appeals for the Federal Circuit (Federal Circuit) today affirmed the earlier decision by the Patent Trial and Appeal Board (PTAB) which found all claims of U.S. Patent No. 10,716 |
LQDA Price Returns
| 1-mo | -21.17% |
| 3-mo | 3.12% |
| 6-mo | 102.42% |
| 1-year | 85.65% |
| 3-year | 335.76% |
| 5-year | 43.10% |
| YTD | 4.32% |
| 2023 | 88.85% |
| 2022 | 30.80% |
| 2021 | 65.08% |
| 2020 | -30.99% |
| 2019 | -80.26% |
Continue Researching LQDA
Want to see what other sources are saying about Liquidia Technologies Inc's financials and stock price? Try the links below:Liquidia Technologies Inc (LQDA) Stock Price | Nasdaq
Liquidia Technologies Inc (LQDA) Stock Quote, History and News - Yahoo Finance
Liquidia Technologies Inc (LQDA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...